CyTuVax has shown the strength of its vaccine adjuvant technology in the Phase 2 clinical trial of a vaccine for hepatitis B non-responders
Press release 17-06-2019
CyTuVax B.V.
Oxfordlaan 55
6229 EV Maastricht
The Netherlands
The PanCaVax project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 836361.